JPH09512708A - グルカンの酵素処理 - Google Patents
グルカンの酵素処理Info
- Publication number
- JPH09512708A JPH09512708A JP7528093A JP52809395A JPH09512708A JP H09512708 A JPH09512708 A JP H09512708A JP 7528093 A JP7528093 A JP 7528093A JP 52809395 A JP52809395 A JP 52809395A JP H09512708 A JPH09512708 A JP H09512708A
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- yeast
- insoluble
- residue
- yeast residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001503 Glucan Polymers 0.000 title claims abstract description 107
- 230000002255 enzymatic effect Effects 0.000 title description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 52
- 210000005253 yeast cell Anatomy 0.000 claims abstract description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 23
- 108010045275 endo-1,6-beta-glucanase Proteins 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 11
- 210000002421 cell wall Anatomy 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 239000012670 alkaline solution Substances 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 241000223260 Trichoderma harzianum Species 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 241000193752 Bacillus circulans Species 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 241000235395 Mucor Species 0.000 claims description 2
- 241000235528 Rhizopus microsporus var. chinensis Species 0.000 claims description 2
- 241000223262 Trichoderma longibrachiatum Species 0.000 claims description 2
- 241000499912 Trichoderma reesei Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims 4
- 238000005903 acid hydrolysis reaction Methods 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 230000020477 pH reduction Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000005063 solubilization Methods 0.000 abstract description 3
- 230000007928 solubilization Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 2
- 239000003292 glue Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 235000019688 fish Nutrition 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 108010014251 Muramidase Proteins 0.000 description 8
- 102000016943 Muramidase Human genes 0.000 description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
- 239000004325 lysozyme Substances 0.000 description 8
- 229960000274 lysozyme Drugs 0.000 description 8
- 235000010335 lysozyme Nutrition 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000277263 Salmo Species 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 101000689231 Aeromonas salmonicida S-layer protein Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000010824 fish disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NIOPZPCMRQGZCE-WEVVVXLNSA-N 2,4-dinitro-6-(octan-2-yl)phenyl (E)-but-2-enoate Chemical compound CCCCCCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1OC(=O)\C=C\C NIOPZPCMRQGZCE-WEVVVXLNSA-N 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000221778 Fusarium fujikuroi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012143 dye reagent concentrate Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- ASHGTUMKRVIOLH-UHFFFAOYSA-L potassium;sodium;hydrogen phosphate Chemical compound [Na+].[K+].OP([O-])([O-])=O ASHGTUMKRVIOLH-UHFFFAOYSA-L 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. (a) β−(1−3)−結合鎖及びβ−(1−6)−結合鎖を有する分 枝β−(1−3)−グルカンを、得られるグルカンがβ−(1−3)−結合グル コースユニットを含有し実質的にβ−(1−6)−結合鎖を含まないような条件 下でβ−(1−6)−グルカナーゼと接触させる、 ことを含む酵母からグルカン生成物を調製する方法。 2. 上記β−(1−6)−グルカナーゼが、Trichoderma longibrachiatum 、Trichoderma reesei 、Trichoderma harzianum 、Rhizopus chinensis、Gibberel la fujikuroi 、Bacillus circulans、Mucor lilmalls、及びAcinetobactor から なる微生物群から得られるものであることを特徴とする特許請求の範囲1記載の 方法。 3. 上記β−(1−6)−グルカナーゼが、Trichoderma harzianum から得ら れるものであることを特徴とする特許請求の範囲1記載の方法。 4. β−(1−3)−グルカン粒子がSaccharomyces 属の酵母に由来するもの であることを特徴とする特許請求の範囲1記載の方法。 5. β−(1,3)−グルカン粒子がSaccharomyces cerevisiaeに由来するも のであることを特徴とする特許請求の範囲4記載の方法。 6. (a) 適切なグルカン−含有酵母細胞を、第一の不溶性酵母残留物を得 るのに適切な条件下において、適切な抽出用水性アル カリ溶液を用いてアルカリ抽出し、 (b) 上記第一の不溶性酵母残留物を、適切な抽出条件下で適切な抽出水性ア ルカリ溶液を用いてホットアルカリ抽出し(該ホットアルカリ抽出は第二の不溶 性酵母残留物を得るために少なくとも2回行う)、ホットアルカリ抽出の後、該 不溶性酵母残留物を回収し、その後、 (c) 上記第二の不溶性酵母残留物を、水を含む適切な条件下において適切な 加水分解用酸を用いてpH約4〜約7の範囲で洗浄して第三の不溶性酵母残留物 を得、洗浄の後、該第三の不溶性酵母残留物を回収し、 (d) 上記第三の不溶性酵母残留物を穏やかな酸性加水分解条件下で加水分解 し(酸加水分解は第四の不溶性酵母残留物を得るために少なくとも3回行う)、 それぞれの酸加水分解の後、酵母残留物を回収し、その後、 (e) 上記第四の不溶性酵母残留物を適切な条件下において水を使用して沸騰 させ(該第四の不溶性酵母残留物の沸騰は第五の不溶性酵母残留物を得るために 少なくとも2回行う)、各沸騰の後、不溶性酵母残留物を回収し、そして、 (f) 上記第五の不溶性酵母残留物を適切な条件下においてエタノール中で沸 騰させ(該第五の酵母残留物のエタノール中での沸騰は第六の不溶性酵母残留物 を得るために少なくとも2回行う)、各沸騰の後、不溶性酵母残留物を回収し、 その後、 (g) 上記第六の不溶性酵母残留物を適切な条件下において水で 洗浄し(該第六の酵母残留物の洗浄は酵母グルカンを得るために少なくとも2回 行う)、各洗浄の後、不溶性酵母残留物を回収する、 段階を含む方法により上記不溶性β−(1−3)−グルカン粒子を調製すること を特徴とする特許請求の範囲1記載の方法。 7. β−(1−6)−結合により付加されたβ−(1−3)−結合側鎖を有す る分枝β−(1−3)−グルカンであり、実質的にβ−(1−6)−結合鎖を含 まないことを特徴とする特許請求の範囲1記載の方法により得られる生成物。 8. β−(1−6)−結合により付加されたβ−(1−3)−結合側鎖を有す る分枝β−(1−3)−グルカンであり、実質的にβ−(1−6)−結合鎖を含 まないことを特徴とする特許請求の範囲6記載の方法により得られる生成物。 9. β−(1−6)−結合により付加されたβ−(1−3)−結合側鎖を有す る分枝β−(1−3)−グルカンであり、実質的にβ−(1−6)−結合鎖を含 まないことに特徴付けられる酵母Saccharomyces 属に特に由来し、とりわけ酵母 種Saccharomyces cerevisiaeに由来する不溶性酵母グルカン粒子。 10. β−(1−3)−結合グルコースユニット主鎖に少なくとも1グルコー スユニットの少なくとも1つのβ−(1−3)−結合側鎖が結合している酵母Sa ccharomyces 属由来の不溶性グルカンを可溶化剤に接触させることを含む、酵母Saccharomyces 属に特に由来し、とりわけ酵母種Saccharomyces cerevisiaeに由 来する酵母からの可溶化β−(1−3)−グルカン粒子の製造方法。 11. 上記可溶化剤がギ酸であり、上記不溶性グルカンが該可溶化剤に70〜 90度の温度範囲において接触されることを特徴とする特許請求の範囲10記載 の方法。 12.特許請求の範囲11記載の方法により得られる可溶化β−(1−3)−グ ルカン生成物。 13. (a) β−(1−3)−結合鎖及びβ−(1−6)−結合鎖を有する 分技β−(1−3)−グルカンである飼料グレード酵母グルカンを、得られるグ ルカンがβ−(1−3)−結合グルコースユニットを含有し実質的にβ−(1− 6)−結合鎖を含まないような条件下でβ−(1−6)−グルカナーゼと接触さ せる、 ことを含む酵母Saccharomyces 属に特に由来し、とりわけ酵母種Saccharomyces cerevisiae に由来する酵母からの飼料用グルカン生成物の製造方法。 14. 上記グルカンがSaccharomyces cerevisiaeに由来することを特徴とする 特許請求の範囲13記載の方法。 15. (a) 酵母細胞壁を、タンパク質及び脂質の抽出を達成するのに適切 な条件下で、水性アルカリ溶液と接触させ、 (b) 得られた抽出酵母細胞壁を上記水性アルカリ溶液から分離し、 (c) 得られた分離酵母細胞を、可溶化細胞壁成分を更にそこから除去するよ うに洗浄し、 (d) 洗浄した酵母細胞壁を中和し、及び (e) 中和し、洗浄した細胞壁を滅菌し、その後、得られた滅菌中和洗浄細胞 壁を乾燥させる、 段階を含む方法により上記飼料グレードグルカンを調製することを特徴とする特 許請求の範囲14記載の方法。 16. β−(1−6)−結合により付加されたβ−(1−3)−結合側鎖を有 する分枝β−(1−3)−グルカンであり、実質的にβ−(1−6)−結合鎖を 含まないことに特徴付けられる特許請求の範囲13記載の方法により得られる生 成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO941581A NO300692B1 (no) | 1994-04-29 | 1994-04-29 | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
NO941581 | 1994-04-29 | ||
PCT/IB1995/000265 WO1995030022A1 (en) | 1994-04-29 | 1995-04-18 | Enzyme treatment of glucans |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007130872A Division JP2007228974A (ja) | 1994-04-29 | 2007-05-16 | グルカンの酵素処理 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09512708A true JPH09512708A (ja) | 1997-12-22 |
JP3992730B2 JP3992730B2 (ja) | 2007-10-17 |
Family
ID=19897060
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52809395A Expired - Lifetime JP3992730B2 (ja) | 1994-04-29 | 1995-04-18 | グルカンの酵素処理 |
JP2007130872A Pending JP2007228974A (ja) | 1994-04-29 | 2007-05-16 | グルカンの酵素処理 |
JP2008290653A Pending JP2009051863A (ja) | 1994-04-29 | 2008-11-13 | 免疫刺激組成物を製造するためのグルカンの使用及び薬剤としてのグルカンの使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007130872A Pending JP2007228974A (ja) | 1994-04-29 | 2007-05-16 | グルカンの酵素処理 |
JP2008290653A Pending JP2009051863A (ja) | 1994-04-29 | 2008-11-13 | 免疫刺激組成物を製造するためのグルカンの使用及び薬剤としてのグルカンの使用 |
Country Status (12)
Country | Link |
---|---|
US (3) | US7883875B2 (ja) |
EP (1) | EP0759089B1 (ja) |
JP (3) | JP3992730B2 (ja) |
AT (1) | ATE222958T1 (ja) |
AU (1) | AU703251B2 (ja) |
CA (1) | CA2189010C (ja) |
DE (1) | DE69527955T2 (ja) |
DK (1) | DK0759089T3 (ja) |
ES (1) | ES2182898T3 (ja) |
FI (1) | FI114807B (ja) |
NO (1) | NO300692B1 (ja) |
WO (1) | WO1995030022A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002539145A (ja) * | 1999-03-12 | 2002-11-19 | バイオテク エイエスエイ | 界面活性剤混合物の使用 |
JP2006122056A (ja) * | 2002-09-20 | 2006-05-18 | Momentum Pharmaceuticals | 骨粗鬆症および他の骨吸収疾患を処置するためのβ−グルカンの使用 |
JP2006166737A (ja) * | 2004-12-13 | 2006-06-29 | Alpron Co Ltd | 酵母由来グルカンの製造方法 |
US7745181B2 (en) | 2004-02-13 | 2010-06-29 | Alpron Co., Ltd. | Process for producing yeast-derived glucan |
JP2010529980A (ja) * | 2007-06-13 | 2010-09-02 | グリコス フィンランド オイ | 栄養組成物 |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO300692B1 (no) * | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
US5786343A (en) * | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
DE19911058B4 (de) | 1999-03-12 | 2004-09-30 | Biotec Asa | Verwendung von nanoskaligen wasserlöslichen β-(1,3)-Glucanen |
US8912165B2 (en) | 1999-03-12 | 2014-12-16 | Biotec Pharmacon Asa | Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents |
US8501710B2 (en) * | 1999-03-12 | 2013-08-06 | Biotec Pharmacon Asa | Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents |
DE19911057C2 (de) * | 1999-03-12 | 2001-01-25 | Cognis Deutschland Gmbh | Haarkosmetische Zubereitungen |
US6875754B1 (en) | 1999-03-12 | 2005-04-05 | Biotec Asa | Use of water-soluble β-(1,3) glucans as agents for producing therapeutic skin treatment agents |
DE19911052A1 (de) * | 1999-03-12 | 2000-09-21 | Cognis Deutschland Gmbh | Sonnenschutzmittel |
DE19911053B4 (de) * | 1999-03-12 | 2004-10-28 | Biotec Asa | Kosmetische und/oder pharmazeutische Zubereitungen |
DE19911056B9 (de) * | 1999-03-12 | 2005-09-08 | Biotec Asa | Kosmetische Zubereitungen und deren Verwendung |
DE19917744A1 (de) * | 1999-04-20 | 2000-10-26 | Cognis Deutschland Gmbh | Dekorative kosmetische Zubereitungen |
DE19917743C2 (de) * | 1999-04-20 | 2003-08-14 | Biotec Asa | Desodorierende Zubereitungen |
DE19920557B4 (de) * | 1999-05-05 | 2004-09-09 | Biotec Asa | Verfahren zur Herstellung von Kollagenfreien kosmetischen Zubereitungen |
US20020009463A1 (en) * | 2000-02-23 | 2002-01-24 | Jan Raa | Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
BE1014638A6 (fr) * | 2002-02-12 | 2004-02-03 | Univ Liege | Methode de preparation de derives de la paroi cellulaire a partir de biomasse. |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
US20050180964A1 (en) | 2003-03-17 | 2005-08-18 | Puntenney Steven B. | Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
JP2004210895A (ja) * | 2002-12-27 | 2004-07-29 | Immudyne Japan:Kk | 免疫機能を有する可能性β−グルカンの製造方法及び用途 |
US20050220846A1 (en) | 2004-04-05 | 2005-10-06 | Puntenney Steven B | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
AU2004218698B2 (en) * | 2004-10-08 | 2011-06-09 | Biotec BetaGlucans AS | Method |
CA2619219C (en) * | 2005-08-10 | 2013-07-02 | Steven Bruce Puntenney | Use of .beta.-1,3 (4)-endoglucanohydrolase, .beta.-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
JP2009528267A (ja) * | 2006-01-17 | 2009-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 治療を増強するグルカン |
US8323644B2 (en) | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US8142798B2 (en) | 2006-04-26 | 2012-03-27 | OmniGen Research, L.L.C. | Augmentation of titer for vaccination in animals |
US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
WO2008057501A2 (en) * | 2006-11-06 | 2008-05-15 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
WO2008102151A1 (en) * | 2007-02-21 | 2008-08-28 | Biotec Pharmacon Asa | Medical uses of glucans |
CA2690918C (en) * | 2007-05-08 | 2016-06-28 | Biopolymer Engineering, Inc. Dba Biothera, Inc. | Particulate-soluble glucan preparation |
CA2705544A1 (en) * | 2007-11-19 | 2009-05-28 | Calanus As | Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites |
EP2224933B1 (en) | 2007-11-26 | 2016-08-03 | GlaxoSmithKline Biologicals SA | Conjugated beta-1,3-linked glucans |
BRPI0900639C1 (pt) * | 2009-02-13 | 2011-12-20 | Hebron Farmaceutica Pesquisa Desenvolvimento E Inovacao Tecnologica Ltda | composição farmacêutica e uso desta para tratamento e/ou prevenção de doenças do trato respiratório |
ES2873502T3 (es) | 2009-03-27 | 2021-11-03 | Bend Res Inc | Proceso de secado por pulverización |
WO2012014978A1 (ja) * | 2010-07-29 | 2012-02-02 | 国立大学法人北海道大学 | 免疫アジュバント |
PT2611530T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Aparelho de secagem por pulverização e métodos de utilização do mesmo |
EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
GB201020190D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucans |
GB201020191D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan gels |
GB201020193D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan compositions |
WO2012120290A2 (en) | 2011-03-04 | 2012-09-13 | Sana Pharma As | Cosmetic formulations |
FR2981075A1 (fr) | 2011-10-11 | 2013-04-12 | Kitozyme | Procede de preparation de glucans a partir d'aspergillus niger |
MD4329C1 (ro) * | 2013-10-30 | 2015-09-30 | Институт Микробиологии И Биотехнологии Академии Наук Молдовы | Procedeu de cultivare a tulpinii de levuri Saccharomyces cerevisiae CNMN-Y-20 |
EP3110437B1 (en) | 2014-02-12 | 2017-11-29 | Omnigen Research, LLC | Composition and method for promoting reduction of heat stress in animals |
PT3212169T (pt) | 2014-10-31 | 2021-05-06 | Bend Res Inc | Processo para formar domínios ativos dispersos numa matriz |
WO2017044832A1 (en) | 2015-09-09 | 2017-03-16 | Omnigen Research, Llc | A composition and/or combination for aquaculture |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2764463A (en) | 1953-05-26 | 1956-09-25 | Underwood Corp | Magnetic recording system |
US3954979A (en) * | 1972-11-24 | 1976-05-04 | Ceres Products Company, Inc. | Process for preparing stabilized yeast and compositions and tableting composition and method |
JPS5432076B2 (ja) | 1973-09-14 | 1979-10-11 | ||
JPS54138115A (en) * | 1978-04-17 | 1979-10-26 | Kirin Brewery | Antiicancer agent |
GB2076418A (en) | 1980-05-22 | 1981-12-02 | Sankyo Co | Hydrolyzed polysaccharide |
JPS6019619B2 (ja) | 1980-09-19 | 1985-05-17 | 株式会社日立製作所 | X線管用回転陽極 |
SE456911B (sv) * | 1983-12-19 | 1988-11-14 | Olle Larm | Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma |
JPS60196195A (ja) | 1984-03-21 | 1985-10-04 | Dainippon Seito Kk | イ−ストグルカンの製造法 |
US4992540A (en) * | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5082936A (en) * | 1984-11-28 | 1992-01-21 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5028703A (en) * | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US4810646A (en) * | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
US5057503A (en) * | 1989-01-23 | 1991-10-15 | The Brigham And Women's Hospital | Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor |
CA1330303C (en) * | 1989-02-20 | 1994-06-21 | Libor Henry Nikl | Composition and process to enhance the efficacy of a fish vaccine |
EP0490995A1 (en) * | 1989-09-08 | 1992-06-24 | Alpha Beta Technology | Method for producing soluble glucans |
US5488040A (en) * | 1989-09-08 | 1996-01-30 | Alpha-Beta Technology, Inc. | Use of neutral soluble glucan preparations to stimulate platelet production |
WO1991003248A2 (en) * | 1989-09-08 | 1991-03-21 | Alpha Beta Technology, Inc. | Method for immune system activation |
US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
US6020324A (en) * | 1989-10-20 | 2000-02-01 | The Collaborative Group, Ltd. | Glucan dietary additives |
CA2040374C (en) * | 1990-07-06 | 1998-06-16 | Gunnar Rorstad | Process for enhancing the resistance of aquatic animals to disease |
NO300692B1 (no) | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
-
1994
- 1994-04-29 NO NO941581A patent/NO300692B1/no not_active IP Right Cessation
-
1995
- 1995-04-18 JP JP52809395A patent/JP3992730B2/ja not_active Expired - Lifetime
- 1995-04-18 DK DK95914485T patent/DK0759089T3/da active
- 1995-04-18 WO PCT/IB1995/000265 patent/WO1995030022A1/en active IP Right Grant
- 1995-04-18 ES ES95914485T patent/ES2182898T3/es not_active Expired - Lifetime
- 1995-04-18 EP EP95914485A patent/EP0759089B1/en not_active Expired - Lifetime
- 1995-04-18 DE DE69527955T patent/DE69527955T2/de not_active Expired - Lifetime
- 1995-04-18 AU AU21464/95A patent/AU703251B2/en not_active Ceased
- 1995-04-18 CA CA2189010A patent/CA2189010C/en not_active Expired - Lifetime
- 1995-04-18 AT AT95914485T patent/ATE222958T1/de active
-
1996
- 1996-10-28 FI FI964339A patent/FI114807B/fi not_active IP Right Cessation
-
2005
- 2005-03-30 US US11/093,427 patent/US7883875B2/en not_active Expired - Fee Related
-
2007
- 2007-05-16 JP JP2007130872A patent/JP2007228974A/ja active Pending
- 2007-12-06 US US11/951,811 patent/US8142785B2/en not_active Expired - Fee Related
-
2008
- 2008-11-13 JP JP2008290653A patent/JP2009051863A/ja active Pending
-
2010
- 2010-12-27 US US12/978,923 patent/US8252295B2/en not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002539145A (ja) * | 1999-03-12 | 2002-11-19 | バイオテク エイエスエイ | 界面活性剤混合物の使用 |
JP4643014B2 (ja) * | 1999-03-12 | 2011-03-02 | バイオテク エイエスエイ | 界面活性剤混合物の使用 |
JP2006122056A (ja) * | 2002-09-20 | 2006-05-18 | Momentum Pharmaceuticals | 骨粗鬆症および他の骨吸収疾患を処置するためのβ−グルカンの使用 |
JP4578393B2 (ja) * | 2002-09-20 | 2010-11-10 | モーメンタム ファーマシューティカルズ | β−グルカンの使用 |
US7745181B2 (en) | 2004-02-13 | 2010-06-29 | Alpron Co., Ltd. | Process for producing yeast-derived glucan |
JP2006166737A (ja) * | 2004-12-13 | 2006-06-29 | Alpron Co Ltd | 酵母由来グルカンの製造方法 |
JP4570949B2 (ja) * | 2004-12-13 | 2010-10-27 | 株式会社アルプロン | 酵母由来グルカンの製造方法 |
JP2010529980A (ja) * | 2007-06-13 | 2010-09-02 | グリコス フィンランド オイ | 栄養組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0759089B1 (en) | 2002-08-28 |
US8252295B2 (en) | 2012-08-28 |
DK0759089T3 (da) | 2003-01-06 |
US20050255565A1 (en) | 2005-11-17 |
DE69527955T2 (de) | 2003-04-10 |
JP2009051863A (ja) | 2009-03-12 |
US7883875B2 (en) | 2011-02-08 |
NO941581D0 (ja) | 1994-04-29 |
WO1995030022A1 (en) | 1995-11-09 |
JP2007228974A (ja) | 2007-09-13 |
US20110104208A1 (en) | 2011-05-05 |
NO300692B1 (no) | 1997-07-07 |
AU703251B2 (en) | 1999-03-25 |
FI964339A0 (fi) | 1996-10-28 |
AU2146495A (en) | 1995-11-29 |
CA2189010C (en) | 2010-07-13 |
NO941581L (no) | 1995-10-30 |
US8142785B2 (en) | 2012-03-27 |
US20080124349A1 (en) | 2008-05-29 |
JP3992730B2 (ja) | 2007-10-17 |
FI964339A (fi) | 1996-10-28 |
ATE222958T1 (de) | 2002-09-15 |
ES2182898T3 (es) | 2003-03-16 |
EP0759089A1 (en) | 1997-02-26 |
DE69527955D1 (de) | 2002-10-02 |
FI114807B (fi) | 2004-12-31 |
CA2189010A1 (en) | 1995-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3992730B2 (ja) | グルカンの酵素処理 | |
US5322841A (en) | Method for producing neutral glucans for pharmaceutical applications | |
EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
US4210641A (en) | Novel polysaccharide extracts and method of use | |
JPH0561255B2 (ja) | ||
CA1197801A (fr) | Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicament les contenant | |
JPH06256208A (ja) | 免疫賦活剤 | |
JP2001504144A (ja) | Gbsトキシン/cm101の精製方法 | |
JP4091136B2 (ja) | 免疫賦活剤 | |
GB2077101A (en) | Antiallergic composition containing streptococci | |
JPH03227939A (ja) | 免疫能賦活化物質及びその製造法 | |
Foley et al. | Studies on the Biology of Cryptococcus: IV. Isolation of a Highly Polymerized Polysaccharide from Encapsulated Strains | |
KR860001213B1 (ko) | 제암 및 면역자극 작용을 갖는 물질의 제조방법 | |
JPH03170503A (ja) | 細胞外エキソポリマー、その調製方法及び該エキソポリマーを含む薬剤組成物 | |
JPH0572921B2 (ja) | ||
JP2841237B2 (ja) | 血圧降下作用を有する菌体水抽出物を有効成分とする血圧降下剤 | |
JPH10212240A (ja) | 粘膜感染に対する経口免疫のための細菌外膜および/または細胞壁の混合物 | |
Pazur | The structure and antigenicity of novel polysaccharides from microorganisms and plants | |
JP2024512375A (ja) | 酵母のグリコシド阻害剤 | |
NL8002108A (nl) | Nieuwe biologisch actieve stof, de bereiding daarvan en deze stof bevattende geneesmiddelen. | |
Springer | PREVENTION OF INTERACTIONS BETWEEN ERYTHROCYTE SURFACE STRUCTURES AND BLOOD-GROUP RELATED TOXIC SUBSTANCES OF MICROBES. Final Progress Report. | |
DK151639B (da) | Fremgangsmaade til fremstilling af tf-100 eller fraktioner heraf med carcinostatisk og immunostimulerende aktivitet | |
JPH06256198A (ja) | 血中コレステロール上昇抑制剤 | |
JPS6191127A (ja) | 抗腫瘍性多糖の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040308 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040609 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050809 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051108 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070516 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070607 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070626 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070725 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110803 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120803 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130803 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |